Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032704 · ClinicalTrials.gov registry record · Phase 2
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
A Phase 2 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT04032704 is a Phase 2 study that was terminated before completion, run by Seagen. The registered enrollment target is 205 participants.
The verdict
NCT04032704, a Phase 2 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.
Interventions
- DRUG pembrolizumab
- DRUG ladiratuzumab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2019-10-09 |
| Est. Completion | 2023-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04032704
The ClinicalTrials.gov registry entry for NCT04032704 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT04032704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04032704 about?
NCT04032704 is a clinical study titled "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors". This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.
What is the current status of trial NCT04032704?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2019-10-09. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT04032704?
The interventions under investigation include: pembrolizumab (DRUG), ladiratuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT04032704?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.